S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 12.36 CNY -1.44%
Market Cap: ¥18.1B

Net Margin

7.8%
Current
Improving
by 4.9%
vs 3-y average of 2.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
7.8%
=
Net Income
¥420.2m
/
Revenue
¥5.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
7.8%
=
Net Income
¥420.2m
/
Revenue
¥5.4B

Peer Comparison

Country Company Market Cap Net
Margin
CN
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
18.1B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

In line with most companies in China
Percentile
66th
Based on 8 721 companies
66th percentile
7.8%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
18.1B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.

Intrinsic Value
13.1 CNY
Undervaluation 6%
Intrinsic Value
Price
S
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
7.8%
=
Net Income
¥420.2m
/
Revenue
¥5.4B
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's current Net Margin?

The current Net Margin for Shenzhen Hepalink Pharmaceutical Group Co Ltd is 7.8%, which is above its 3-year median of 2.8%.

How has Net Margin changed over time?

Over the last 3 years, Shenzhen Hepalink Pharmaceutical Group Co Ltd’s Net Margin has increased from 6.1% to 7.8%. During this period, it reached a low of -14.4% on Dec 31, 2023 and a high of 12.2% on Dec 31, 2024.

Back to Top